Health
Sinopharm shares phase 2 data on inactivated COVID-19 vaccine – FierceBiotech
Sinopharm has published clinical data on its adjuvanted SARS-CoV-2–inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the pandemic coronavirus.

Sinopharm has published clinical data on its adjuvanted SARS-CoV-2inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the pandemic coronavirus.
Most of the frontrunners in the COVID-19 vaccine race are using relatively unproven approaches to immunization. BioNTech, in partnership with Pfizer, and Moderna are advancing mRNA vaccines, a type of prophylactic that has never been approved. AstraZen…
-
Noosa News19 hours ago
Commissioner thanks police officer who threw a speed radar at a car
-
Noosa News17 hours ago
No matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News18 hours ago
Defence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News18 hours ago
Good character references restricted in rape cases in Queensland